Adventitial Expression of Recombinant Endothelial Nitric Oxide Synthase Gene Reverses Vasoconstrictor Effect of Endothelin-1

Abstract

The present study was designed to determine the effect of recombinant endothelial nitric oxide synthase (eNOS) gene expression on reactivity of canine basilar arteries to endothelin-1 (ET-1). Experiments were performed ex vivo. The arteries were exposed (30 minutes at 37°C) to adenoviral vectors encoding eNOS gene (AdCMVeNOS) or β-galactosidase reporter gene (AdCMVβ-Gal). Twenty-four hours after transduction, transgene expression was evident mainly in the vascular adventitia. Rings of control (nontransduced), AdCMVβ-Gal- and AdCMVeNOS-transduced arteries with and without endothelium were suspended for isometric tension recording. Levels of guanosine 3′,5′ -cyclic monophosphate (cGMP) were measured by radioimmunoassay. During contractions to uridine 5′-triphosphate, ET-1 (10⁻¹⁰ to 3×10⁻9 mol/L) caused further increase in tension in control and AdCMVβ-Gal-transduced arteries. In contrast, ET-1 caused concentration-dependent relaxations of AdCMVeNOS-transduced arteries. The relaxations to ET-1 in AdCMVeNOS-transduced arteries were endothelium-independent They were abolished by N^G-nitro-L-argininemethyl ester or by chemical treatment of adventitia with paraformaldehyde before gene transfer. ET-1 (10⁻⁹ mol/L) significantly increased intracellular cGMP levels in AdCMVeNOS-transduced arteries without endothelium. In arteries transduced with AdCMVeNOS, higher concentrations (10⁻⁹ to 3×10⁻⁸ mol/L) of ET-2 also caused relaxations, whereas ET-3 and sarafotoxin, a selective ET_B receptor agonist, did not produce any relaxations. The relaxations to ET-1 in AdCMVeNOS-transduced arteries were strongly reduced by BQ-123 (10⁻⁷ mol/L), an ET_A receptor antagonist, but were not affected by BQ-788 (3×10⁻⁷ mol/L), an ET_B receptor antagonist These results suggest that genetically modified adventitia can produce nitric oxide and cause relaxations in response to ET-1 via activation of ET_A receptors. Our findings support a novel concept that successful transfer and expression of recombinant eNOS gene can lead to a qualitative change in responsiveness to vasoconstrictor substances.

Keywords

Endothelin Adenoviral vector Gene transfer Nitric oxide synthase Receptor Cerebral vasospasm

Endothelin (ET)-1 is a potent vasoconstrictor peptide (Yanagisawa et al., 1988), and it is generally accepted that ET-1 may be an important substance involved in the pathogenesis of a number of cardiovascular disorders including systemic hypertension, pulmonary hypertension, coronary arterial spasm, and atherosclerosis (Ivy et al., 1997; Lerman et al., 1991; Nayler, 1990; Steward et al., 1991), In the cerebral circulation, ET-1 is regarded as a putative mediator of cerebral vasospasm, which is a major cause of morbidity and mortality in patients with subarachnoid hemorrhage (Asano et al., 1989; Cosentino and Katusic, 1994; Suzuki et al., 1992; Willett et al., 1994; Zuccarello et al., 1996).

Nitric oxide (NO), produced by endothelial nitric oxide synthase (eNOS), is a potent vasodilator and plays an essential role in the regulation of vascular tone (Bredt and Snyder, 1994; Moncada, Palmer and Higgs, 1991), A recent advance in recombinant DNA technology has made it possible to increase local NO production in the vascular wall by increasing expression of eNOS (Janssens et al., 1996; von der Leyen et al., 1995). Our previous in vitro and in vivo studies have confirmed that recombinant eNOS gene can be transferred using adenoviral vectors into adventitial layer overlying canine cerebral arteries, and that expression of eNOS gene in the adventitia can augment vasodilator effect of bradykinin and calcium ionophore A23187 (Chen et al., 1997a,b; Tsutsui et al., 1998). During preliminary studies, we noticed that expression of recombinant eNOS gene in canine basilar arteries could convert the contractile responses to ET-1 into relaxations. This observation suggested that successful transfer and expression of recombinant eNOS gene may lead to a qualitative change in responsiveness of cerebral arteries to vasoconstrictor substances. Therefore, the present study was designed to characterize the mechanism of ET-1–induced relaxations of isolated canine basilar arteries expressing recombinant eNOS gene.

MATERIALS AND METHODS

Construction, propagation, and purification of adenoviral vectors

The adenoviral vector encoding eNOS gene (AdCMVeNOS), driven by the cytomegalovirus immediate early promoter, was generated through homologous recombination (Spector and Samaniego, 1995). These vectors, based on serotype 5 wild adenovirus, have been made replication-deficient by a deletion of the early region 1 (E1), followed by an insertion of the cDNA sequence for bovine aortic endothelial cell eNOS (kindly provided by Dr. David G. Harrison, Emory University, Atlanta, GA). The generation, propagation, purification, and evaluation of the adenoviral vector containing eNOS gene were described in detail previously (Chen et al., 1997b). The recombinant adenoviral vector encoding β-galactosidase gene driven by cytomegalovirus promoter (AdCMVβ-Gal), used in all experiments as control, was a kind gift of Dr. James M. Wilson (University of Pennsylvania, Philadelphia, PA).

Gene transfer

All procedures were in accordance with the institutional guidelines of the Mayo Clinic. Experiments were performed ex vivo on rings (3-mm long) of basilar arteries taken from mongrel dogs (15 to 20 kg), anesthetized with 30 mg/kg (intravenous) sodium pentobarbital. To remove intraluminal blood, arterial rings were gently rinsed with cold modified Krebs-Ringer bicarbonate solution (control solution) consisting of NaCl 118.3, KCl 4.7, CaCl₂ 2.5, MgSO₄ 1.2, KH₂PO₄ 1.2, NaHCO₃ 25.0, calcium-ethylenediamine-tetraacetic acid (EDTA) 0.026 and glucose 11.1 (mmol/L). In certain rings, the endothelium was removed mechanically. Endothelial removal was accomplished by gently sliding an arterial ring over a steel needle (19 to 22 gauge) abraded by sandpaper, using two pairs of fine forceps under a microscope. The rings were assigned randomly for gene transfer. Cerebral arteries do not have external elastic lamina (Lee, 1995; Rosenblum, 1994), and it is impossible to mechanically remove the adventitia. Therefore, to disrupt function of the adventitial layer it was chemically treated with paraformaldehyde (the artery placed on a steel needle was soaked into phosphate-buffered saline [PBS] solution containing 4% paraformaldehyde for 15 seconds). Arterial rings were then incubated with adenoviral vectors (10¹⁰ pfu/mL) in minimum essential medium (MEM; containing 0.1% bovine serum albumin, 100 U/mL penicillin and 100 μg/mL streptomycin) for 30 minutes at 37°C. This was followed by incubation in fresh MEM for 24 hours at 37°C in a CO₂ incubator (5% CO₂/95% air; Forma Scientific, Inc.).

Histochemical and immunohistochemical analyses of gene expression

For histochemical staining of β-galactosidase, the rings of basilar arteries were fixed for 30 minutes in 2% paraformaldehyde/0.2% glutaraldehyde in PBS. The rings were rinsed in PBS, and placed in 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside reagent for 2 hours, The stained vessels were frozen in O.C.T. compound (Miles, Inc.). Serial 5 μm cross sections were cut from each ring and counterstained with nuclear fast red. For immunohistochemical staining of recombinant eNOS, arterial rings were frozen in O.C.T. compound and serial 5 μm cross sections were cut. After immersion fixation in acetone (4°C), the sections were incubated in 0.1% sodium azide/0.3% hydrogen peroxide, and then incubated with 5% normal goat serum/PBS-Tween 20 to block the nonspecific protein binding sites. A monoclonal antibody against eNOS (5 μg/mL, 1:50 of stock; Transduction Laboratory) was applied for 60 minutes at room temperature, followed by incubations with biotinylated rabbit anti-mouse F(ab′)2 (1:200, 20 minutes) secondary antibody and peroxidase conjugated-streptavidin (1:300, 20 minutes) (Vector Laboratories, Inc.). After a 30-second immersion in 0.1-mol/L sodium acetate buffer (pH 5.2), eNOS immunoreactivity was visualized with 3-amino-9-ethylcarbazole and hematoxylin counterstaining.

Quantitative analysis of β-galactosidase protein

Expression of β-galactosidase protein in vessels was quantified by an enzyme-linked immunosorbent assay (ELISA). Twenty-four hours after gene transfer, arterial rings without endothelium were homogenized in a solution containing 0.1 mol/L K₂HPO₄, 0.2% Triton X-100, and 10⁻³ mol/L phenylmethylsulfonyl fluoride, pH 7.8 at 4°C. After a centrifugation at 12000xg for 10 minutes, β-galactosidase protein levels in supernatants were determined using β-galactosidase ELISA kit (5 Prime 3 Prime, Inc.). Total protein levels in the supernatants were measured by a DC Protein Assay Kit (Bio-Rad).

Analyses of vascular reactivity

Twenty-four hours after gene transfer, each ring was connected to an isometric force transducer (Grass FT03; Grass Instrument Co.) and suspended in an organ chamber filled with 25 mL modified Krebs-Ringer bicarbonate solution (control solution; pH 7.4, 37°C) aerated with 94% O₂–6% CO₂, Isometric tension was recorded continuously. The rings were allowed to stabilize at a resting tension of 0.2 to 0.4 g for 1 hour. Each ring was then gradually stretched to the optimal point of its length-tension curve (approximately 3.0 g) as determined by the contraction to 10⁻⁵ mol/L uridine 5′ -triphosphate (UTP) (Katusic et al., 1987). All experiments were performed in the presence of 10⁻⁵ mol/L indomethacin to exclude the possible influence of endogenous cyclo-oxygenase. To evaluate relaxation responses, the rings were contracted with UTP (3×10⁻⁶ to 10⁻⁵ mol/L) before the addition of agonists. Concentration-response curves were obtained in a cumulative fashion. Several rings prepared from the same artery were studied in parallel. The relaxations were expressed as a percentage of maximal relaxations induced by 3×10⁻⁴ mol/L papaverine added at the end of each experiment. In experiments with diethylamine NONOate (DEA-NONOate), the median effective concentration (EC₅₀) was calculated for each ring by linear interpolation between the two concentrations evoking responses just above and below 50% of the maximum.

Measurement of cGMP

A radioimmunoassay technique was used to determine the tissue content of guanosine 3′,5′ -cyclic monophosphate (cGMP). Twenty-four hours after gene transfer, 10⁻⁵ mol/L indomethacin and 10⁻³ mol/L 3-isobutyl-1-methylxanthine were added to the incubation medium containing arterial rings without endothelium, to eliminate the influence of cyclo-oxygenase and to inhibit the degradation of cGMP by phosphodiesterases, respectively. After the incubation for 30 minutes, certain rings were stimulated with 10⁻⁹ mol/L ET-1 for 2 minutes. Then the rings were removed from the medium and immediately frozen in liquid nitrogen. Samples were homogenated in a cooled solution of 100% ethanol and 1 N HCl. Samples were then centrifuged (4000 rpm, at 4°C for 10 minutes) and supernatant poured into a clean tube and placed in a 55°C water bath under nitrogen to dry off the ethanol. After the tube was dry the sample was reconstituted with a Tris buffer. The assay was run using a kit from Amersham. Protein assay was conducted by a DC Protein Assay Kit (Bio-Rad). This assay is similar to the procedure described by Lowry.

Drugs

The following pharmacological agents were used: ET-1, ET-2, ET-3 (Phoenix Pharmaceuticals, Inc.), BQ-123, BQ-788 (Research Biochemicals Interational), UTP, sarafotoxin S6c, (L-NAME), indomethacin, papaverine hydrochloride (Sigma), and diethylamine NONOate (DEA-NONOate; Cayman Chemical Co.). Drugs were dissolved in distilled water so that volumes of <0.15 mL were added to the organ chambers. Concentrations of all drugs are expressed as final molar (mol/L) concentration in the control solution. For experiments with BQ-123, BQ-788, and L-NAME, these drugs were added 15 minutes before obtaining the concentration-response curve for each vasodilator agent.

Statistical analysis

The results are expressed as means± SD; n refers to the number of animals studied. Each set of concentration-response relationship was statistically analyzed by repeated measures analysis of variance (RM-ANOVA). Levels of β-galactosidase and cGMP, and EC₅₀ values in response to DEA-NONOate in different groups, were compared using ANOVA with Bonferroni/Dunn's post-hoc test. Statistical significance was accepted at the level of P < .05.

RESULTS

Relaxations to ET-1

During contractions induced by UTP (10⁻⁵ M), ET-1 (10⁻¹⁰ to 3×10⁻⁹ mol/L) caused concentration-dependent relaxations of AdCMVeNOS-transduced basilar arteries (Fig. 1A). In contrast, ET-1 caused only additional contractions in control (nontransduced) and AdCMVβ-Gal–transduced arteries The relaxations to ET-1 were not affected by the removal of endothelial cells (Fig. 1B). The typical responses to ET-1 in AdCMVβ-Gal– and AdCMVeNOS-transduced arteries without endothelium are presented in Fig. 2. The relaxations to ET-1 in endothelium-denuded arteries after eNOS gene transfer were abolished in the presence of L-NAME (3×10⁻⁴ mol/L), an inhibitor of nitric oxide synthase (NOS) (Fig. 3).

FIG. 1.

Responses to endothelin-1 in nontransduced (Control), AdCMVβ-Gal–transduced (β-Gal), and AdCMVeNOS-transduced (eNOS) basilar arteries with (A) and without (B) endothelium. Responses were evaluated during contractions induced by uridine 5′-triphosphate. Data are shown as means ± SD and are expressed as percent of maximal relaxations induced by papaverine (3×10⁻⁴ mol/L); 100% = 3.1 ± 0.6 g (n = 9), 2.7 ± 0.8 g (n = 9) and 2.7 ± 0.9 g (n = 9; A), and 3.1 ± 0.5 g (n = 9), 2.7 ± 0.8 g (n = 9) and 3.3 ± 0.9 g (n = 9; B), for Control, β-Gal gene-transduced, and eNOS gene-transduced arteries, respectively. Effect of endothelin-1 in eNOS arteries was significantly different from corresponding control and β-Gal arteries; P < .05 by repeated measure analysis of variance.

FIG. 2.

Typical recordings of responses to endothelin-1 in AdCMVβ-Gal-transduced and AdCMVeNOS-transduced basilar arteries without endothelium. Responses were obtained during contractions induced by uridine 5′ -triphosphate (UTP; 10⁻⁵ mol/L).

FIG. 3.

Effect of N^G-nitro-L-arginine methyl ester (L-NAME; 3 × 10⁻⁴ mol/L) and chemical treatment of adventitia with paraformaldehyde (PFA) on relaxations to endothelin-1 in AdCMVeNOS-transduced (eNOS) basilar arteries without endothelium. Responses were evaluated during contractions induced by uridine 5′-triphosphate. Data are shown as mean ± SD and are expressed as percent of maximal relaxations induced by papaverine (3 × 1 0⁻⁴ mol/L); 100% = 4.0 ± 1.4 g (n = 5), 4. 5 ± 0.9 g (n = 5), and 3.5 ± 0.7 g (n = 5) for untreated arteries and arteries treated with L-NAME and PFA, respectively. Effects of endothelin-1 in L-NAME and PFA treated arteries were significantly different from control; P < .05 by repeated measure analysis of variance.

Effect of chemical treatment of adventitia on gene transfer and vascular reactivity

Twenty-four hours after exposure to AdCMVβ-Gal and AdCMVeNOS, expression of recombinant proteins was evident mainly in the adventitia (Fig. 4). Chemical treatment of arterial adventitia with paraformaldehyde before gene transfer, abolished expression of recombinant proteins detected by histochemical or immunohistochemical staining. Abolition of β-galactosidase protein expression in those chemically treated arteries was verified also by ELISA (Table 1). The same treatment abolished the relaxations to ET-1 in AdCMVeNOS-transduced arteries (Fig. 3). In contrast, paraformaldehyde did not reduce relaxations to DEA-NONOate, a donor of nitric oxide (Table 2).

FIG. 4.

Histochemical staining of β-galactosidase (A, B, C) and immunohistochemical staining of eNOS (D, E, F) expression in basilar arteries without endothelium 24 hours after gene transfer. Transgene expression was compared among nontransduced arteries (A, D), AdCMVβ-Gal-transduced (B) and AdCMVeNOS-transduced (E) arteries, and AdCMVβ-Gal-transduced (C) and AdCMVeNOS-transduced (F) arteries pretreated with 4% paraformaldehyde. Original magnification; ×100.

TABLE 1.

Effect of chemical treatment of adventitia on expression of recombinant β-galactosidase protein in basilar arteries without endothelium

	β-galactosidase protein(ng/mg total protein)	n
Control (non-transduced)	0.14 ± 0.12	5
β-Gal	157.1 ±45.9*	5
β-Gal (PFA-treated)	0.60 ±0.54	5

Chemical treatment of adventitial layer with paraformaldehyde (PFA) was conducted before β-Gal gene transfer as described in Methods. Values are mean ± SD; n = number of dogs.

Statistically different from control and β-Gal (PFA-treated); P < 0.05 by ANOVA.

TABLE 2.

Effect of chemical treatment of adventitia on EC₅₀ and maximal relaxation in response to DEA-NONOate in e-NOS gene-transduced basilar arteries without endothelium

	EC₅₀(−log mol/L)	Maximalrelaxation	n
Control	8.06 ± 0.12	95.2 ± 1.6	5
PFA-treated	8.34 ± 0.19	94.8 ± 3.0	5

The chemical treatment of adventitial layer with paraformaldehyde (PFA) was conducted before eNOS gene transfer as described in Methods. Relaxations were obtained during contractions to uridine 5′-triphosphate. Relaxations are expressed as percent of maximal relaxation induced by papaverine (3 × 10⁻⁴ mol/L). Values are mean ± SD. EC₅₀ indicates median effective concentration; n = number of dogs.

Relaxations to ET-1, ET-2, ET-3, and sarafotoxin

Relaxations to ET-1, ET-2, ET-3, and sarafotoxin, a selective ET_B receptor agonist, were compared in AdCMVeNOS-transduced basilar arteries without endothelium (Fig. 5A). ET-2 caused relaxations in AdCMVeNOS-transduced arteries, however, the concentrations required to induce detectable and maximal relaxations were higher than those of ET-1. In arteries contracted with UTP, ET-3, and sarafotoxin caused only further increase in vascular tone.

FIG. 5.

Responses to endothelin-1 (ET-1), endothelin-2 (ET-2), endothelin-3 (ET-3), and sarafotoxin (A), and effect of BQ-123 (10⁻⁷ mol/L) and BQ-788 (3 × 10⁻⁷ mol/L) on relaxation responses to ET-1 (B), in AdCMVeNOS-transduced (eNOS) basilar arteries without endothelium. Responses were evaluated during contractions induced by uridine 5′-triphosphate. Data are shown as mean ± SD and are expressed as percent of maximal relaxations induced by papaverine (3 × 10⁻⁴ mol/l); 100% = 3.7 ± 0.5 g (n = 7),4.5 ± 1.1 g (n = 7), 3.7 ± 0.6 g (n = 7), and 4.4 ± 0.8 g (n =7) for ET-1, ET-2, ET-3 and sarafotoxin (A), and 3.8 ± 0.5 g (n = 5), 3.5 ± 0.6 g (n = 5) and 3.6 ± 0.9 g (n = 5) for untreated arteries and arteries treated with BQ-123 and BQ-788 (B), respectively.

Effect of BQ-123 and BQ-788 on relaxations to ET-1

Relaxations to ET-1 in AdCMVeNOS-transduced basilar arteries without endothelium, were studied in the presence of BQ-123, a selective ET_A receptor antagonist, or BQ-788, a selective ET_B receptor antagonist (Fig. 5B). BQ-123 (10⁻⁷ mol/L) abolished the relaxations to ET-1. In contrast, BQ-788 in the same concentration (10⁻⁷ mol/L; data not shown) and even in a higher concentration (3×10⁻⁷ mol/L) did not affect the relaxations to ET-1 (Fig. 5B).

Contractions to ET-1

ET-1 (10⁻¹⁰ to 10⁻⁸ mol/L) caused concentration-dependent increase in base line tension in basilar arteries that were not contracted by UTP. These contractions were significantly smaller in AdCMVeNOS-transduced arteries compared to those in AdCMVβ-Gal–transduced arteries (Fig. 6). In contrast, contractile responses to UTP were not different between AdCMVβ-Gal–transduced and AdCMVeNOS-transduced arteries (Fig. 7).

FIG. 6.

Contractile responses to endothelin-1 in AdCMVβ-Gal-transduced (β-Gal) and AdCMVeNOS-transduced (eNOS) basilar arteries with (A) and without (B) endothelium. Endothelin-1 was added to quiescent arterial rings. Data are shown as mean ± SD and are expressed as absolute values of generated tension (g). Effects of endothelin-1 in eNOS arteries were significantly different from effects in β-Gal gene-transduced arteries; P < .05 by repeated measure analysis of variance.

FIG. 7.

Contractile responses to uridine 5′-triphosphate (UTP) in AdCMVβ-Gal-transduced (β-Gal) and AdCMVeNOS-transduced (eNOS) basilar arteries with (A) and without (B) endothelium. UTP was added to quiescent arterial rings. Data are shown as mean ± SD and are expressed as absolute values of generated tension (g).

Measurement of intracellular cGMP

No significant difference was detected in basal cGMP levels among control, AdCMVβ-Gal–transduced and AdCMVeNOS-transduced basilar arteries without endothelium (Fig. 8). ET-1 (10⁻⁹ mol/L) significantly increased cGMP level only in AdCMVeNOS-transduced arteries (Fig. 8).

FIG. 8.

Effect of endothelin-1 (10⁻⁹ mol/L) on guanosine 3′,5′-cyclic monophosphate (cGMP) production in nontransduced (Control), AdCMVβ-Gal–transduced (β-Gal), and AdCMVeNOS-transduced (eNOS) basilar arteries without endothelium (E-). Data are shown as mean ± SD. *Significantly different from all other factors; P < .05 by analysis of variance.

DISCUSSION

This is the first study to examine the vascular reactivity to endothelins in cerebral arteries expressing recombinant eNOS gene. The major new findings are that (1) expression of recombinant eNOS gene causes reversal of vasoconstrictor effects of ET-1 into vasodilatation, and that (2) this reversal is mediated by activation of adventitial ET_A receptors and subsequent increased formation of NO.

Successful gene transfer and expression of recombinant proteins was confirmed by β-galactosidase histochemistry and eNOS immunohistochemistry. Positive staining of these recombinant proteins was detected predominantly in the vascular adventitia, being consistent with results of our previous ex vivo and in vivo gene transfer studies (Chen et al., 1997a,b; Tsutsui et al., 1998). In canine basilar arteries transduced with AdCMVeNOS, ET-1 produced concentration-dependent relaxations during contractions to UTP, however, it caused only additional contractions in nontransduced control arteries and AdCMVβ-Gal–transduced arteries. In certain vascular beds, ET-1 reportedly can induce relaxations by a release of vasodilator substances including NO and prostacyclin from the endothelium (Ohlstein et al., 1990; Pinheiro and Malik, 1993), or by a direct activation of potassium channels on smooth muscle cells (Hasunuma et al., 1990). In contrast, in canine cerebral arteries ET-1 causes only contractions (present study; Asano et al., 1989; Saito et al., 1991). Thus, ET-1–induced relaxations observed in the present study represent a phenomenon specific for genetically engineered arteries. The relaxations to ET-1 of AdCMVeNOS-transduced arteries were mediated by production of NO, since L-NAME, an inhibitor of NOS, abolished the relaxations, and ET-1 significantly increased cGMP levels in the vascular wall. The increased cGMP levels in response to ET-1 were not detected either in non transduced control vessels or AdCMVβ-Gal–transduced arteries, showing the selective effect of eNOS gene transfer on cGMP formation in response to ET-1.

Our results show that the treatment of adventitia with paraformaldehyde before gene transfer abolished transgene expression of recombinant proteins. We used this technique to confirm that the effect of eNOS gene transfer on vasoreactivity to ET-1 was mediated by adventitial expression of recombinant eNOS. It is not feasible to mechanically remove the adventitial layer of cerebral arteries because cerebral arteries do not have external elastic lamina (Rosenblum, 1994). The chemical treatment of adventitia can be used to selectively disrupt the adventitial function because this treatment did not affect the smooth muscle functions. Contractile responses to UTP and ET-1 (Fig. 3) and relaxations to DEA- NONOate (Table 2), a donor of NO, were maintained in paraformaldehyde-treated arteries. The chemical treatment of adventitia abolished the relaxations to ET-1 in AdCMVeNOS-transduced arteries, indicating that the relaxant effect of ET-1 was dependent on the presence of intact adventitia. Thus, these findings reinforce the idea that ET-1 stimulates NO production in the vascular adventitia transduced with AdCMVeNOS, and causes subsequent cGMP formation and relaxations of arterial smooth muscle.

In AdCMVeNOS-transduced basilar arteries without endothelium, ET-2 also caused relaxations during UTP-induced contractions, however, ET-3 did not produce any relaxations. Previous studies have indicated that ET-1 and ET-2 exhibit relatively higher affinity for ET_A receptors than ET-3 (Arai et al., 1990; Sakurai et al., 1990). In addition, sarafotoxin, a selective ET_B receptor agonist (Heyl et al., 1993; Williams et al., 1991), did not induce relaxations in arteries transduced with AdCMVeNOS, suggesting that activation of ET_A receptors located on the vascular adventitia is involved in the relaxations to ET-1 and ET-2. This concept is further supported by the present results showing that BQ-123, a selective ET_A receptor antagonist (Douglas, Meek and Ohlstein, 1994; Ihara et al., 1995), almost abolished ET-1-induced relaxations, whereas BQ-788, a selective ET_B receptor antagonist (Ishikawa et al., 1994; Karaki, Sudjarwo and Hori, 1994) was without effect. In our previous ex vivo and in vivo gene transfer studies on canine cerebral arteries, electron microscopy immunogold labeling indicated that expression of recombinant eNOS protein was localized to adventitial fibroblasts (Chen et al., 1997a; Tsutsui et al., 1998). Existing evidence suggests that ET receptors are present on fibroblasts, and that activation of these receptors leads to increase in intracellular free Ca²⁺ concentration (Gardner, Maher and Aviv, 1989; Ohnishi-Suzaki et al., 1990; Peacock et al., 1992). Therefore, it is very likely that ET-1 may activate recombinant eNOS enzyme via ET_A receptor-mediated increase in intracellular Ca²⁺, thereby facilitating production of NO in adventitial fibroblasts.

ET-1 caused concentration-dependent contractions in arteries that were not contracted by UTP. These contractions were significantly reduced in arteries with AdCMVeNOS transduction. The effect of recombinant eNOS was comparable in arteries with and without endothelial cells, suggesting that release of NO from the adventitia was responsible for the suppression of contractile responses to ET-1. The selectivity of recombinant eNOS inhibitory effect on contractions to ET-1 was shown by the fact that contractions to UTP were identical in AdCMVβ-Gal–transduced and AdCMVeNOS-transduced arteries.

In the cerebral circulation, ET-1 is regarded as a putative mediator of cerebral vasospasm after subarachnoid hemorrhage (Asano et al., 1989; Cosentino and Katusic, 1994; Suzuki et al., 1992; Willette et al., 1994; Zuccarello et al., 1996). An exact pathogenesis of this arterial narrowing is not completely understood; however, it has been postulated that occurrence of vasospasm correlates with an increase of ET-1 concentrations in plasma and CSF (Ehrenreich et al., 1992; Suzuki et al., 1990; Suzuki et al., 1992). In addition, decreased availability of NO is thought to be an important factor responsible for the development of vasospasm (Katusic et al., 1993; Macdonald and Weir, 1991; Pluta et al., 1996). Our results indicate that expression of recombinant eNOS gene may have beneficial effect due to (1) restoration of NO formation and (2) reversal of vasoconstrictor effect of ET-1 into relaxations. A recent study has shown that perivascular expression of recombinant β-galactosidase could be obtained by intracisternal injection of adenoviral vectors in dogs with developed vasospasm after subarachnoid hemorrhage (Muhonen et al., 1997). Therefore, the delivery of adenoviral vectors with functional expression of recombinant eNOS in cerebral arteries may provide a feasible approach to prevent cerebral vasospasm.

The present study shows that contractile responses to ET-1 could be reversed to relaxations by adventitial expression of recombinant eNOS gene. This novel vasodilator mechanism may have important implications in development of gene therapy for various vascular disorders associated with enhanced ET-1 production.

Footnotes

Abbreviations used

Acknowledgment

The authors thank Ms. Janet Beckman for preparing the manuscript.

References

Arai

Hori

Aramori

Ohkabo

Nakanishi

(1990) Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348:730–732

Asano

Ikegaki

Suzuki

Sato

Shibuya

(1989) Endothelin and the production of cerebral vaospasm in dogs. Biochem Biophys Res Commun 159:1345–1351

Bredt

Snyder

(1994) Nitric oxide: a physiological messenger molecule. Annu Rev Biochem 63:175–195

Chen

AFY

Jiang

Crotty

Tsutsui

Smith

O̕Brien

Katusic

(1997a) Effects of in vivo adventitial expression of recombinant endothelial nitric oxide synthase gene in cerebral arteries. Proc Natl Acad Sci USA 94:12568–12573

Chen

AFY

O̕Brien

Tsutsui

Kinoshita

Pompili

Crotty

Spector

Katusic

(1997b) Expression and function of recombinant endothelial nitric oxide synthase gene in canine basilar artery. Circ Res 80:327–335

Cosentino

Katusic

(1994) Does endothelin-1 play a role in the pathogenesis of cerebral vasospasm? Stroke 25:904–908

Douglas

Meek

Ohlstein

(1994) Novel receptor antagonists welcome a new era in endothelin biology. Trends Pharmacol Sci 15:313–316

Ehrenreich

Lange

Near

Anneser

Schoeller

Schmid

Winkler

Kehrl

Schmiedek

Goebel

(1992) Long term monitoring of immunoreactive endothelin-1 and endothelin-3 in ventricular cerebrospinal fluid, plasma, and 24-h urine of patients with subarachnoid hemorrhage. Res Exp Med 192:257–268

Gardner

Maher

Aviv

(1989) Calcium mobilization and Na⁺/H⁺ anti port activation by endothelin in human skin fibroblast. FEBS Lett 256:38–42

10.

Hasunuma

Rodman

O̕Brien

McMurtry

(1990) Endothelin-1 causes pulmonary vasodilation in rats. Am J Physiol 259:H48–H54

11.

Heyl

Cody

Flynn

Welch

Reynolds

Doherty

(1993) Truncated analogues of endothelin and sarafotoxin are selective for the ET_B receptor subtype. Peptide Res 6:238–241

12.

Ihara

Yamanaka

Ohwaki

Ozaki

Fukami

Ishikawa

Towers

Yano

(1995) [³H] BQ-123, a highly specific and reversible radioligand for the endothelin ET_A receptor subtype. Eur J Pharmacol 274:1–6

13.

Ishikawa

Ihara

Noguchi

Mase

Mino

Saeki

Fukuroda

Fukami

Ozaki

Nagase

Nishikibe

Yano

(1994) Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci USA 91:4892–896

14.

Ivy

Parker

Ziegler

Galen

Kinsella

Tuder

Abman

(1997) Prolonged endothelin A receptor blockade attenuates chronic pulmonary hypertension in the ovine fetus. J Clin Invest 99: 1179–1186

15.

Janssens

Bloch

Nong

Gerard

Zoldhelyi

Collen

(1996) Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats. J Clin Invest 98:317–324

16.

Karaki

Sudjarwo

Hori

(1994) Novel antagonist of endothelin ET_B1 and ET_B2 receptors, BQ-788: effects on blood vessel and small intestine. Biochem Biophys Res Commun 205:168–173

17.

Katusic

Milde

Cosentino

Mitrovic

(1993) Subarachnoid hemorrhage and endothelial L-arginine pathway in small brain stem arteries in dogs. Stroke 24:392–399

18.

Katusic

Shepherd

Vanhoutte

(1987) Endotheliumdependent contraction to stretch in canine basilar arteries. Am J Physiol 252:H671–H673

19.

Lee

(1995) Morphology of cerebral arteries. Pharacol Therapeut 66:149–173

20.

Lerman

Edwards

Hallett

Heublein

Sandberg

Burnett

(1991) Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 325:997–1001

21.

Macdonald

Weir

BKA

(1991) A review of hemoglobin and the pathogenesis of cerebral vasospasm. Stroke 22:971–982

22.

Moncada

Palmer

RMJ

Higgs

(1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109–142

23.

Muhonen

Ooboshi

Welsh

Davidson

Heistad

(1997) Gene transfer to cerebral blood vessels after subarachnoid hemorrhage. Stroke 28:822–829

24.

Nayler

(1990) Endothelin: isoforms, binding sites and possible implications in pathology. Trends Pharmacol Sci 11:96–99

25.

Ohlstein

Vickery

Sauermelch

Willette

(1990) Vasodilation induced by endothelin: role of EDRF and prostanoids in rat hindquarters. Am J Physiol 259:H1835–H1841

26.

Ohnishi-Suzaki

Yamaguchi

Kusuhara

Adachi

Abe

Kimura

(1990) Comparison of biological activities of endothelin-1, -2 and -3 in murine and human fibroblast cell lines. Biochem Biophys Res Commun 166:608–614

27.

Peacock

Dawes

Shock

Gray

Reeves

Laurent

(1992) Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts. Am J Resp Cell & Mol Biol 7:492–99

28.

Pinheiro

Malik

(1993) Mechanisms of endothelin-1-induced pulmonary vasodilatation in neonatal pigs. J Physiol 469:739–752

29.

Pluta

Thompson

Dawson

Snyder

Boock

Oldfield

(1996) Loss of nitric oxide synthase immunoreactivity in cerebral vasospasm. J Neurosurg 84:648–654

30.

Rosenblum

(1994) Some features of the functional anatomy of human cerebral blood vessels. In: The Human Brain Circulation ( Bevan

Bevan

, eds.), Totowa, New Jersey, Humana Press, pp 23–35

31.

Saito

Shiba

Yanagisawa

Masaki

Kimura

Yamada

Mima

Shigeno

Goto

(1991) Endothelins: vasoconstrictor effects and localization in canine cerebral arteries, Br J Pharmacol 103:1129–1135

32.

Sakurai

Yanagisawa

Takuwa

Miyazaki

Kimura

Goto

Masaki

(1990) Cloning of a cDNA encoding a non-isopeptideselective subtype of the endothelin receptor, Nature 348:732–735

33.

Spector

Samaniego

(1995) Construction and isolation of recombinant adenovirus with gene replacements, Methods Mol Genet 7:31–4

34.

Steward

Kubac

Costello

Cernacek

(1991) Increased plasma endothelin-1 in the early hours of acute myocardial infarction, J Am Coli Cardiol 18:38–43

35.

Suzuki

Sato

Suzuki

aka

Tsuchiya

lino

Yamanaka

Ishihara

Shimoda

(1990) Endothelin immunoreactivity in cerebrospinal fluid of patients with subarachnoid hemorrhage, Ann Med 22:233–236

36.

Suzuki

Masaoka

Hirata

Amori

Marumo

Isotani

Hirakawa

(1992) The role of endothelin-1 in the origin of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 77:96–100

37.

Tsutsui

Chen

AFY

O̕Brien

Crotty

Katusic

(1998) Adventitial expression of recombinant endothelial nitric oxide synthase gene restores nitric oxide production in cerebral arteries without endothelium. Arterioscler Thromb Vase Biol 18:1231–1241

38.

von der Leyen

Gibbon

Morishita

Lewis

Zhang

Nakajima

Kaneda

Cooke

Dzau

(1995) Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proe Natl Aead Sci USA 92: 1137–1141

39.

Willette

Zhang

Mitchell

Sauermelch

Ohlstein

Sulpizio

(1994) Nonpeptide endothelin antagonist. Cerebrovascular characterization and effects on delayed cerebral vasospasm. Stroke 25:2450–2455

40.

Williams

Jr Jones

Pettibone

Lis

Clineschmidt

(1991) Sarafotoxin S6c: an agonist which distinguishes between endothelin receptor subtypes. Biochem Biophys Res Commun 175:556–561

41.

Yanagisawa

Kurihara

Kimura

Tomobe

Kobayashi

Mitsui

Yazaki

Goto

Masaki

(1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415

42.

Zuccarello

Soattin

Lewis

Breu

Hallak

Rapoport

(1996) Prevention of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor antagonists. J Neurosurg 84:503–507